A vaccine targeting an enzyme that breaks down NAD+, called CD38, counteracts signs of aging in mice. 


Immunity

Model: Ten-month-old male EFAD mice 
Dosage: 14.4 ppm of alfatradiol in diet for five months

USC Study: Longevity-Promoting Drug Counteracts a Genetic Predisposition to Alzheimer's

The drug alfatradiol, also known as 17ɑ-estradiol, reduces cognitive errors on a test of memory and lowers neuronal plaques in mice genetically predisposed to Alzheimer’s disease.

(The University of Southern California | College Matchpoint)

Researchers unveil data suggesting the drug alfatradiol improves signs of frailty, reduces cognitive errors, and reduces neuronal plaques in mice with a genetic predisposition to Alzheimer’s disease.

Brain &amp; Neurons

Model: UM-HET3 mice and 5XFAD mice 
Dosage: UM=HET3 mice received 180 mg/kg canagliflozin in chow starting at seven months of age, and FXFAD mice received 180 mg/kg canagliflozin in chow beginning at three months of age

New Study: Diabetes Medication Improves Cognition and Alleviates Alzheimer’s Progression

The diabetes drug canagliflozin improves learning and memory in middle-aged male mice and reduces brain plaques in Alzheimer’s model mice.

The FDA-approved diabetes medication canagliflozin improves cognition in a mouse model of Alzheimer’s disease in males only.

Model: C3B6F1 hybrid mice 
Dosage: 42 mg/kg of rapamycin and 1.44 mg/kg of trametinib in food starting at 6 months of age

Latest Research: Two FDA-Approved Drugs Additively Extend Lifespan

Researchers at the Max Planck Institute have unveiled that combining trametinib with rapamycin, drugs used in cancer treatment, extends average lifespan by 29% in female mice and 27% in male mice, respectively.

(The study’s lead author, Linda Partridge | The Biologist)

Combining two cancer treatment drugs, trametinib and rapamycin, extends lifespan by 29% and 27% in middle-aged female and male mice, respectively.

Aging &amp; Longevity

Latest Human Trial from the Buck Institute Shows Plasma Exchange Lowers Biological Age

A new human study shows that a procedure involving the replacement of blood plasma with a fresh solution (therapeutic plasma exchange) lowers a measure of how quickly the body is aging (biological age).

(The Buck Institute for Research on Aging | Facebook)

In a first-of-its-kind human trial, participants who underwent therapeutic plasma exchange exhibited significantly lowered biological age.

Search Result: FDA

Anti-Aging Vaccine Boosts Strength, Memory & NAD+ in New Study

USC Study Suggests Longevity-Promoting Drug Counteracts a Genetic Predisposition to Alzheimer’s

Diabetes Medication Improves Cognition and Alleviates Alzheimer’s Progression, Suggests New Study

Latest Research: Two FDA-Approved Drugs Additively Extend Lifespan

Latest Human Trial from the Buck Institute Shows Plasma Exchange Lowers Biological Age